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Introduction
Cartilage is a connective tissue of diverse embryonic
origin, that serves multiple prenatal and postnatal func-
tions. Cartilage provides structural support for the early
embryo, forms a template for developing endochondral
bones, provides for rapid postnatal growth of the skeleton,
cushions the joints, allows for flexible facial structure, and
repairs fractured bones. Chondrocytes exhibit a life cycle
of proliferation, differentiation, maturation, and apoptosis;
the rate of each of these processes is dependent on tem-
poral and spatial cues within the body. Identifying and
characterizing these cues will reveal the molecular basis of
cartilage form and function. Mutations or deregulation of
these determinants of chondrogenesis and cartilage
development can lead to skeletal malformation, limited
skeletal function, or predisposition to injury. Congenital
skeletal malformations are common and can be caused by
a number of factors: inherited individual or multiple gene
mutations; or acquired gene–environment interactions.
Recent progress in linkage analysis and positional cloning
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Abstract
Cartilage serves multiple functions in the developing embryo and in postnatal life. Genetic mutations
affecting cartilage development are relatively common and lead to skeletal malformations, dysfunction
or increased susceptibility to disease or injury. Characterization of these mutations and investigation of
the molecular pathways in which these genes function have contributed to an understanding of the
mechanisms regulating skeletal patterning, chondrogenesis, endochondral ossification and joint
formation. Extracellular growth and differentiation factors including bone morphogenetic proteins,
fibroblast growth factors, parathyroid hormone-related peptide, extracellular matrix components, and
members of the hedgehog and Wnt families provide important signals for the regulation of cell
proliferation, differentiation and apoptosis. Transduction of these signals within the developing
mesenchymal cells and chondrocytes results in changes in gene expression mediated by transcription
factors including Smads, Msx2, Sox9, signal transducer and activator of transcription (STAT), and
core-binding factor alpha 1. Further investigation of the interactions of these signaling pathways will
contribute to an understanding of cartilage growth and development, and will allow for the
development of strategies for the early detection, prevention and treatment of diseases and disorders
affecting the skeleton.
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has identified many genetic mutations associated with
human skeletal syndromes or predispositions to certain
skeletal diseases (Table 1). Sequencing the human
genome also allows for the identification of the genetic
loci of many bone- and cartilage-associated genes that
serve as candidate links with additional skeletal disorders.
Because of genetic background or gene–environment
interactions, single gene mutations can cause different
disorders. Furthermore, the same phenotype can be the
result of mutations in different genes [1]. Complex dis-
eases that are subject to multifactorial influences, such as
osteoarthritis [2,3] provide the greatest challenges ahead.
An understanding of the mechanisms that regulate chon-
drogenesis and cartilage development will, therefore, con-
tribute to early gene-based detection of diseases and
disorders that affect cartilage, and will provide the neces-
sary foundation for novel prevention and treatment strate-
gies, such as gene therapy and tissue engineering.
Genetic and biomechanical determinants of
chondrogenesis
Although chondrocytes appear to be a uniform cell type
comprising the majority of the cells in cartilage, the
origins and elaborations of the cartilage lineage are
diverse. Chondrocytes arise from cranial neural crest
cells (CNCCs) of the neural ectoderm, cephalic meso-
derm, sclerotome of the paraxial mesoderm, or somato-
pleure of the lateral plate mesoderm. Terminal
differentiation of chondrocytes results in different types of
cartilage: hyaline; elastic; and fibrous. Chondrocyte differ-
entiation, therefore, provides unique opportunities for the
study of ‘what, when and how’ a repertoire of morpho-
genetic signals are integrated into the developmental
program. A number of molecules have been shown to
function in cartilage formation. These include classes of
extracellular ligands and their cognate receptors and
cytoplasmic transducers [4], nuclear receptors [5], tran-
scription factors or DNA-binding proteins [6], matrix
proteins [7], matrix modifiers including matrix metallo-
proteinases [8], adhesion molecules [9] and the
cytoskeleton [10]. The functions of these molecules have
been reviewed in the literature cited and references
therein. Although much is known about the gene prod-
ucts that characterize the cartilage phenotype, very little
is known about the combinations of gene products that
reflect the genesis of the cartilage cell lineage. Further-
more, the growth and development of the skeleton are
particularly susceptible to the influence of biomechanical
forces [11]. Mechanical loading regulates the shape,
repair, regeneration, and senescence of the skeleton.
Mechanical signals are transduced through the extracellu-
lar matrices, modify cell–matrix and cell–cell interactions,
and impact on transcriptional responses. The interplay,
therefore, between genetic and biomechanical determi-
nants controls the integrity of cartilage produced both in
vivo and in vitro [12].
Mesenchymal cell condensation
Chondroprogenitor mesenchymal cells aggregate into
chondrogenic nodules as a necessary step in chondrocyte
differentiation. This condensation process is dependent
on signals initiated by cell–matrix and cell–cell adhesion,
and these signals are modified by the cell’s response to
growth and differentiation factors in the extracellular envi-
ronment. Condensation is hallmarked by changes in cell
adhesion and cytoskeletal architecture [9,13]. The roles of
N-cadherin, fibronectin, syndecans, tenascins, throm-
bospondins, neural cell adhesion molecule, focal adhesion
kinase and paxillin in chondrogenic condensation have
been reported. These molecules are expressed in
restricted temporal and spatial patterns that correlate with
chondroprogenitor cell condensation. Perturbations of the
functions of these molecules leads to disruption in cell
aggregation and inhibition of normal cartilage formation.
Cell–cell and cell–matrix interactions activate cytoplasmic
kinases, phosphatases and GTPases that can, in turn, be
modulated by signaling from growth and differentiation
factors such as the bone morphogenetic proteins (BMPs)
and Wnts [14–16]. Although chondrogenesis is regulated
by combinatorial signaling of a large number of factors,
cell condensation can be regarded as the major event of
the cell’s commitment to the cartilage lineage, after which
tissue-specific transcription factors and structural proteins
begin to accumulate.
Bone morphogenetic proteins
BMPs are a pleiotropic group of extracellular ligands, first
coined due to the ability of demineralized bone matrix
(containing BMPs) to induce bone formation when
injected into muscular compartments of animals [17].
Since then, a large number of molecules of the BMP
family, and its superfamily, the transforming growth factor-
betas (TGF-βs) have been cloned and identified, with
mammalian BMP2 and BMP4 being the prototypes of the
Drosophila homologue, decapentaplegic [18,19]. BMPs
signal through transmembrane serine threonine kinase
receptors [20]. There are two types of receptors, type I
and type II, each having a number of subtypes and varying
affinities to the different BMPs. Downstream from the
receptors are various cytoplasmic and nuclear transduc-
ers, both positive and negative [21]. Over the past three
decades since the discovery of BMPs, their ability to
induce ectopic bone and cartilage formation and the
mechanism of induction have been meticulously dissected
[22]. BMPs, however, have been demonstrated to function
in multiple systems and stages of development [19]. The
diversity and specificity, therefore, of cellular competence
and response towards BMPs remain to be topics of
intense investigation. The pleiotropic actions of BMPs can
be concentration-dependent, and BMP signaling can be
regulated by positive and negative cellular feedback
events [20]. Concomitantly, BMP signals are modulated
by BMP binding proteins and other growth and differentia-Arthritis Research    Vol 4 No 2 Shum and Nuckolls
Table 1
Selected genes causal to skeletal diseases and disorders
OMIM # Gene name Gene symbol Diseases and disorders
114290 Sry-related HMG-box gene 9 SOX9 Acampomelic campomelic dysplasia
Campomelic dysplasia
Campomelic dysplasia with autosomal sex reversal
120110 Collagen, type X alpha-1 COL10A1 Metaphyseal chondrodysplasia, Schmid type
Spondylometaphyseal dysplasia, Japanese type
120140 Collagen, type II alpha-1 COL2A1 Achondrogenesis, type II
Achondrogenesis-hypochondrogenesis, type II
Hypochondrogenesis
Kniest dysplasia
Osteoarthritis with mild chondrodysplasia
Spondyloepimetaphyseal dysplasia, Strudwick type
Spondyloepiphyseal dysplasia, various types
Spondylometaphyseal dysplasia, congenital type
Spondyloperipheral dysplasia
Stickler syndrome, type I
Wagner syndrome
120150 Collagen, type I alpha-1 COL1A1 Ehlers–Danlos syndrome, types I and VIIA
Osteogenesis imperfecta, types I, II, III, and IV
120160 Collagen, type I alpha-2 COL1A2 Ehlers–Danlos syndrome, type VII-B
Osteogenesis imperfecta, types II, III, and IV
Osteogenesis imperfecta/Ehlers–Danlos crossover syndrome
Marfan syndrome, atypical
120180 Collagen, type III alpha-1 COL3A1 Arterial and aortic aneurysms
Ehlers–Danlos syndrome, types III and IV
120190 Collagen, type V alpha-2 COL5A2 Ehlers–Danlos syndrome, types I and II
120215 Collagen, type V alpha-1 COL5A1 Ehlers–Danlos syndrome, types I, II, and mixed type
120260 Collagen, type IX alpha-2 COL9A2 Epiphyseal dysplasia, multiple, type 2
Intervertebral disc disease
120270 Collagen, type IX alpha-3 COL9A3 Epiphyseal dysplasia, multiple, type 3
Epiphyseal dysplasia, multiple, with myopathy
120280 Collagen, type XI alpha-1 COL11A1 Stickler syndrome, type II
Marshall syndrome
120290 Collagen, type XI alpha-2 COL11A2 Sensorineural deafness, autosomal dominant nonsyndromic
Otospondylomegaepiphyseal dysplasia
Stickler syndrome, type III
Weissenbacher–Zweymuller syndrome
120360 Matrix metalloproteinase 2 MMP2 Osteolysis, idiopathic, Saudi type
121050 Fibrillin 2 FBN2 Contractural arachnodactyly, congenital
123101 Muscle segment homeobox 2 MSX2 Craniosynostosis, Boston-type
Parietal foramina 1
125505 Deoxyribonuclease I DNASE1 Systemic lupus erythematosus susceptibility
133700 Exostosin 1 EXT1 Exostoses, multiple, type 1
Chondrosarcoma
133701 Exostosin 2 EXT2 Exostoses, multiple, type II
134797 Fibrillin 1 FBN1 Marfan syndrome, various types
Ectopia lentis, familial
Marfanoid skeletal syndrome
Mass syndrome
Shprintzen–Goldberg syndrome
Continued oppositeAvailable online http://arthritis-research.com/content/4/2/094
Table 1
Continued
OMIM # Gene name Gene symbol Diseases and disorders
134934 Fibroblast growth factor receptor 3 FGFR3 Achondroplasia
Crouzon syndrome with acanthosis nigricans
Hypochondroplasia
Muenke syndrome
Multiple myeloma
Saddan dysplasia
Thanatophoric dysplasia, types I and II
136350 Fibroblast growth factor receptor 1 FGFR1 Pfeiffer syndrome
139250 Growth hormone 1 GH1 Growth hormone deficiency
Isolated growth hormone deficiency, type I
Kowarski syndrome
139320 Guanine nucleotide-binding protein, GNAS1 Mccune–Albright syndrome
alpha-stimulating activity polypeptide 1 Albright hereditary osteodystrophy
Pituitary adenoma, ACTH-secreting
142461 Heparan sulfate proteoglycan HSPG2 Schwartz–Jampel syndrome, type 1 
of basement membrane, perlecan Dyssegmental dysplasia, Silverman–Handmaker type
142958 Homeobox A11 HOXA11 Radioulnar synostosis with amegakaryocytic thrombocytopenia
147620 Interleukin 6 IL6 Interleukin 6 polymorphism associated with systemic onset 
juvenile rheumatoid arthritis
154870 Matrix gamma-carboxyglutamic MGP Keutel syndrome
acid protein
156845 Microphthalmia-associated MITF Waardenburg syndrome, type IIA
transcription factor Tietz albinism–deafness syndrome
157660 Mitochondrial RNA-processing RMRP Cartilage–hair hypoplasia
endoribonuclease (RNA component of)
168450 Parathyroid hormone PTH Hypoparathyroidism
168468 Parathyroid hormone receptor 1 PTHR1 Metaphyseal chondrodysplasia, Murk Jansen type
Chondrodysplasia, Blomstrand type
176943 Fibroblast growth factor receptor 2 FGFR2 Apert syndrome
Beare–Stevenson cutis gyrata syndrome
Craniosynostosis, nonsyndromic unicoronal
Crouzon syndrome
Jackson–Weiss syndrome
Pfeiffer syndrome
Saethre–Chotzen syndrome
190180 Transforming growth factor, beta-1 TGFB1 Camurati–Engelmann disease
193500 Paired box gene 3 PAX3 Waardenburg syndrome, types I, II, and III
Waardenburg syndrome with meningomyelocele
Rhabdomyosarcoma, alveolar
Craniofacial–deafness–hand syndrome
203500 Homogentisate 1,2-dioxygenase HGD Alkaptonuria
217000 Complement component 2 C2 Complement component 2 deficiency
222600 Solute carrier family 26, member 2 SLC26A2 Achondrogenesis, type IB
Atelosteogenesis, type II
Diastrophic dysplasia
249100 Familial Mediterranean fever gene MEFV Familial Mediterranean fever
277900 ATPase, Cu(2+)-transporting, ATP7B Wilson Disease
beta polypeptide
300202 Sedlin SEDL Spondyloepiphyseal dysplasia, late
300300 Bruton agammaglobulinemia BTK Agammaglobulinemia, X-linked associated with
tyrosine kinase septic arthritis
Continued overleafArthritis Research    Vol 4 No 2 Shum and Nuckolls
Table 1
Continued
OMIM # Gene name Gene symbol Diseases and disorders
308000 Hypoxanthine guanine HPRT1 Gout, HPRT-related
phosphoribosyltransferase 1 Lesch–Nyhan syndrome
311850 Phosphoribosylpyrophosphate PRPS1 Gout, PRPS-related
synthetase I
312865 Short stature homeobox SHOX Short stature, idiopathic
Leri–Weill dyschondrosteosis
Langer mesomelic dysplasia
600211 Runt-related transcription factor 2 RUNX2 Cleidocranial dysplasia
600310 Cartilage oligomeric matrix protein COMP Epiphyseal dysplasia
Pseudoachondroaplasia
600725 Sonic hedgehog SHH Holoprosencephaly 3
600726 Indian hedgehog IHH Brachydactyly type A1
600856 Cyclin-dependent kinase inhibitor 1C CDKN1C Beckwith–Wiedemann syndrome
600946 Growth hormone receptor GHR Laron syndrome
Short stature, autosomal dominantand idiopathic
601105 Cathepsin K CTSK Pycnodysostosis
601146 Growth/differentiation factor 5 GDF5 Acromesomelic dysplasia, Hunter–Thompson type
Brachydactyly, type C
Chondrodysplasia, Grebe type
601199 Calcium-sensing receptor CASR Hypercalciuric hypercalcemia
Hypercalciuric hypocalcemia
Hyperparathyroidism
Hypocalcemia
Hypocalciuric hypercalcemia
Hypoparathyroidism, various types
601309 Patched PTCH Basal cell nevus syndrome
Basal cell carcinoma, sporadic
601769 Vitamin D receptor VDR Vitamin D-resistant rickets, type II
602109 Matrilin 3 MATN3 Multiple epiphyseal dysplasia
602337 Receptor tyrosine kinase-like  ROR2 Brachydactyly, type B1
Orphan receptor 2 Robinow syndrome, autosomal recessive
602365 Cathepsin C CTSC Papillon–Lefevre syndrome
Haim–Munk syndrome
602727 Chloride channel 7 CLCN7 Osteopetrosis, Autosomal Recessive, Infantile Malignant
602991 Noggin NOG Symphalangism, proximal
Multiple synostoses syndrome 1
603400 Wnt1-inducible signaling  WISP3 Arthropathy, progressive pseudorheumatoid of childhood
pathway protein 3
603499 Tumor necrosis factor receptor  TNFRSF11A Expansile osteolysis, familial
superfamily, 11A Paget disease of bone 2
604142 Tyro protein tyrosine  TYROBP Polycystic lipomembranous osteodysplasia with sclerosing
kinase-binding protein leukoencephalopathy
604283 Proteoglycan 4 PRG4 Camptodactyly–arthropathy–coxa vara–pericarditis syndrome
604592 T cell immune regulator 1 TCIRG1 Osteopetrosis, autosomal recessive
604831 Ellis–Van Creveld syndrome gene EVC Ellis–Van Creveld syndrome
Weyers acrodental dysostosis
605145 Ank ANKH Craniometaphyseal dysplasia, autosomal dominant
605380 Fibroblast growth factor 23 FGF23 Hypophosphatemic rickets, autosomal dominant
605420 Aristaless-like 4, ALX4 Parietal foramina 2
605740 Sclerostin SOST Sclerosteosis
Mutations in a number of genes have been shown to cause congenital skeletal disorders, often with defects in cartilage formation as the primary
basis. Others predispose the individual towards skeletal diseases such as arthritis. The completed sequence of the human genome opens the door
for rapid identification of additional genetic mutations associated with human diseases and disorders. Functional genomics and the characterization
of molecular mechanisms bridging genotypes to phenotypes are our challenges to realize solutions for the prevention, detection, diagnosis and
therapy of these diseases and disorders. Data extracted from Online Mendelian Inheritance in Man (OMIM) [113].tion factors, resulting in combinatorial signaling and diver-
gent outcomes dependent on the modifiers, which can be
either genetic or environmental [23].
Sox9
The Sry-type, high-mobility group (HMG)-box containing
transcription factor SOX9 comes closest to serving the
function of a master regulator of the chondrocyte lineage
of any molecule yet characterized. Sox9 expression is
directly induced by BMP signaling [24–26]. In humans,
SOX9 haploinsufficiency (Online Mendelian Inheritance in
Man [OMIM] number 114290) results in campomelic dys-
plasia (a lethal skeletal malformation syndrome) with XY
sex reversal [27]. During embryogenesis, Sox9 is
expressed in all chondroprogenitors, coincident with the
expression of type II collagen. Sox9 regulates chondroge-
nesis through binding to essential DNA sequence motifs
in chondrocyte-specific enhancer elements of the type II
and type XI collagen genes and the cartilage-derived
retinoic-acid-sensitive protein. Sox9 can even bind to, and
activate, these DNA enhancer sequences in cartilage
genes that have been transfected into nonchondrocytes
[28–30]. Mouse embryonic stem cells with null mutations
of Sox9 do not form cartilage in teratomas [31]. Animals
that are heterozygous null for Sox9 exhibit defects in all
cartilage primordia and present a phenotype similar to
human campomelic dysplasia [32]. The phosphorylation of
Sox9 by cAMP-dependent protein kinase A in response to
parathyroid hormone-related peptide (PTHrP) signaling
regulates the binding of Sox9 to responsive elements in the
collagen promoters [33,34]. Furthermore, Sox9 is known to
form complexes with L-Sox5 and Sox6, and may also inter-
act with other chondrocyte-associated transcription factors
[35]. The regulation of this key player in chondrogenesis,
therefore, is at the level of expression, protein modification,
complex formation, and transcriptional activation.
Patterning and cell fate determination
Chondrogenesis can be divided into two interdependent
processes: patterning; and cell fate determination. Pattern
formation is the process during which number, size, and
shape of the cartilaginous template is delineated and
established. Cell fate determination is the process by
which the combinatorial interactions of genetic and envi-
ronmental factors serve to direct the developmental pro-
gression of a cell lineage. Cell fate is progressively
restricted, and tissue specificity is gradually committed.
The actions of these determinants are dependent upon
concentration, time, and position. Patterning and cell fate
determination are governed by a series of tissue interac-
tions, which include interactions between adjacent com-
ponents of segmental structures, or between juxtaposed
epithelium and mesenchyme. Chondrogenesis during
craniofacial and limb development best illustrates the
complexity and hierarchy of regulatory mechanisms under-
lying the developmental program. During vertebrate
morphogenesis, CNCCs, as well as limb bud mesenchy-
mal cells, respond to BMP4 [36]. Depending on the timing
of exposure to BMP4, these mesenchymal cells may
undergo apoptosis or chondrogenesis. The orchestration
of the apoptotic and chondrogenic response results in the
formation and delineation of cartilaginous structures in the
developing face and limbs. Studies have shown that the
regulation of BMP4-mediated divergent morphogenetic
outcome is dependent on both positive and negative mod-
ulators, at the level of ligands, cytoplasmic signals, and
transcription factors.
Craniofacial development
Cartilages of the craniofacial region are largely derived
from CNCCs [37]. CNCCs are a specialized population of
ectodermal cells in origin, and arise from the lateral margin
of the developing hindbrain. At the early somite stage of
the embryo, the hindbrain is segmented into compart-
ments called rhombomeres. CNCCs that are generated
from the hindbrain are thus segment-specific, and these
cells undergo epithelial to mesenchymal transformation,
leave the crest and migrate towards the forming face. The
cells populate the branchial arches, expand, and eventu-
ally differentiate into cartilage and several other cell types.
A series of experiments showed that CNCCs are respon-
sive to BMP4 and, depending on the stage of develop-
ment, there can be different outcomes. Instrumental to the
differential responses is a homeodomain transcription
factor, Msx2, which mediates craniofacial and limb mor-
phogenesis [38,39]. A gain of function mutation in the
human MSX2 gene (OMIM 123101) causes Boston-type
craniosynostosis, while loss of function mutations in this
gene cause parietal foramina type I [40]. Msx2 is present
in all stages of CNCC development: formation; migration;
and differentiation. In the developing rhombomeres, BMP4
and Msx2 are coexpressed in rhombomeres 3 and 5 and
correlate with extensive CNCC apoptosis observed in
these rhombomeres, which results in limited contribution
of CNCC to the craniofacial skeleton [41]. Apoptosis is
the mechanism of eliminating CNCCs, which are not nec-
essary for differentiation, and the occurrence of apoptosis
in alternate segments of the hindbrain serves to pattern
the migrating CNCCs into three major streams. In these
early premigratory crest cells, BMP4 induces Msx2
expression and causes apoptosis [41]. Overexpression of
Msx2 along the cephalic neural tube results in increased
apoptosis, suggesting that Msx2 is the mediator of BMP4
action [42]. In rhombomeres that produce a significant
number of CNCCs, the action of BMP is restricted by a
Wnt antagonist, cSFRP2 [43]. Taken together, the pat-
terning of CNCC formation within the neural tube is regu-
lated by both positive and negative signals modulated by
BMP. At later stages, Msx2 functions as a repressor of
chondrogenesis without inducing cell death [44]. During
migration, Msx2 and Sox9 are coexpressed in migrating
CNCCs. Msx2 serves to repress the function of Sox9
Available online http://arthritis-research.com/content/4/2/094such that these cells are allowed to migrate and arrive at
their target site before overt differentiation occurs. A domi-
nant negative form of Msx2 accelerates the rate and extent
of chondrogenesis in CNCCs in cultures, demonstrating
that, when the function of Msx2 is inhibited, cells are de-
repressed, and allowed to differentiate [44]. Msx2 also
functions as a repressor of chondrogenesis during the for-
mation of Meckel’s cartilage in the mandibular division of
the first branchial arch [26]. Overexpression of Msx2 in the
developing mandible disrupts the formation of Meckel’s
cartilage. Interestingly, Msx2 expression closely borders
areas of cartilage differentiation and is tightly juxtaposed
to the expression of Sox9. This suggests that Msx2 nor-
mally functions to delineate and define the boundaries for
cartilage formation. Implanting BMP4-soaked beads in the
developing mandible induces the expression of both Sox9
and Msx2 [26]. The relative level of expression of these
antagonistic molecules, however, is dependent on posi-
tional cues within the mandible. These positional cues may
be genes that are locally expressed in a specific region of
the developing mandible. These genes may modify cellular
competence to respond to BMP4, and consequently the
expression pattern and profile of Sox9 and Msx2 induced
by BMP4. It is this relative expression of Sox9 and Msx2
that determines whether ectopic cartilage will form around
the bead. The regional molecular differences in the
mandible that account for differential expression of Sox9
and Msx2 remain to be explored.
Limb development
During skeletogenesis in the developing limb bud, chon-
droprogenitor cells initiate their differentiation while neigh-
boring cells undergo apoptosis, thus defining the
boundaries of the developing skeletal elements. Mes-
enchymal condensations followed by chondrocyte differ-
entiation and maturation occur in digital zones, whereas
mesenchymal cells undergo apoptotic elimination in inter-
digital web zones to give rise to the delineation of the
digits [45]. Failure of one of these processes results in
limb malformations such as polydactyly or syndactyly of
soft or hard tissues. BMPs regulate not only the chondro-
genic and the apoptotic responses of the mesenchymal
cells, but also specify digit identity, as well as participate
in the generation, maintenance, and regression of the
apical ectodermal ridge (a structure that governs the proxi-
mal–distal patterning of the limb bud) [46–48]. BMPs,
however, do not pattern each region of the limb bud indi-
vidually. Rather, evidence supports the hypothesis that
BMPs participate in communicating cell fate decisions
interactively between adjacent regions of the limb bud.
Interdigital mesenchyme destined to undergo apoptosis in
vivo produces cartilage when it is isolated away from the
digits and developed in vitro [49,50]. Furthermore, digit
identity is specified by the correspondingly more posterior
interdigital tissue [48]. Interestingly, similar to the early
patterning of the CNCC, Msx2 is also a mediator of BMP-
regulated apoptosis in the interdigital mesenchyme [51].
Recent data suggest that the specificity of BMP for multi-
ple actions during limb morphogenesis reflects different
activities of the receptor subtypes transducing the BMP
signal [52]. BMP receptor type IB appears to be the nec-
essary mediator of BMP-induced chondrogenesis
[53–55], although overexpression of the receptor, or con-
stitutive activation of the receptor can also cause exces-
sive apoptosis [56,57]. A significant challenge of future
research is to distinguish between the downstream signal-
ing pathways from the BMP receptor subtypes. These dif-
ferences may provide a molecular basis for the specific
and often antithetic responses elicited by BMPs within
developing limb buds and other tissues.
Chondrocyte maturation
Embryonic cartilage is destined for one of several fates; it
can remain as permanent cartilage, such as on the articu-
lar surfaces of bones, or it can provide a template for the
formation of bones through the process of endochondral
ossification (EO) [58,59]. Most of the bones of the axial
and appendicular skeleton, and some of the bones of the
craniofacial skeleton, develop through this process. The
following two sections describe recent advances in under-
standing the molecular regulation of chondrocyte matura-
tion during EO and joint formation.
Endochondral ossification
The anlagen of long bones develop as relatively homoge-
neous elongated masses of cartilage tissue surrounded by
a perichondrium. Signaling between the perichondrium and
the chondrocytes (discussed below) causes cells in the
center of the anlagen to initiate progression in their matura-
tion program to prepare a site of ossification. These chon-
drocytes undergo several rounds of more rapid proliferation,
and then arrest in their cell cycle. The postmitotic cells
change their morphology, alter their gene expression, and
remodel their extracellular matrix to become hypertrophic
chondrocytes (Fig. 1). Whereas proliferating and articular
chondrocytes synthesize a cartilage matrix composed
mostly of type II collagen, hypertrophic chondrocytes cease
expressing type II and express type X collagen, which is rec-
ognized as a marker of hypertrophic cells in the chondro-
cyte lineage. The cartilage matrix also becomes mineralized,
and the hypertrophic chondrocytes undergo apoptosis.
Prior to their death, they deposit the angiogenic factor, vas-
cular endothelial growth factor (VEGF), into their extracellu-
lar matrix, which promotes the invasion of blood vessels into
the cartilage tissue [60]. The blood vessels bring chondro-
clasts, osteoblasts and osteoclasts into the new ossification
center, which begin removing the mineralized cartilage
matrix and forming bone tissue.
The process of chondrocyte maturation expands from this
initial central site toward the ends of the forming bones,
with the zones of chondrocyte proliferation, cell cycle
Arthritis Research    Vol 4 No 2 Shum and Nuckollsarrest, hypertrophy, and apoptosis arranged sequentially
(Fig. 1). The perichondrium along the shaft differentiates
into a collar of bone that expands toward the ends of the
developing bone in pace with the advance of hypertrophic
chondrocytes. During postnatal development, these carti-
lage structures, called growth plates, are ‘sandwiched’
between the bony metaphysis and epiphysis, and serve as
factories for the rapid production of new bone. Regulation
and coordination of the rates of chondrocyte proliferation,
hypertrophic maturation, apoptosis, and bone collar forma-
tion are essential to normal bone morphogenesis. Human
genetic disorders affecting EO, such as achondroplasia
and chondrodysplasias, are relatively common. Positional
cloning in affected pedigrees has contributed to the identi-
fication of genes that regulate bone development
[59,61–63]. Further analysis of the regulatory mechanisms
in animal models has provided an understanding of the
interactions of these genes. Recent advances in under-
standing the regulation of EO have resulted from the
studies of fibroblast growth factor receptors (FGFRs),
Indian hedgehog (Ihh), PTHrP, BMPs and core-binding
factor (Cbfa1). Although retinoids, nitric oxide, hypoxia,
vitamin D, estrogens, and other small molecules, as well as
extracellular matrix molecules and biomechanical signals
contribute to the regulation of chondrocyte differentiation
and maturation, this review will focus primarily on peptide
and glycoprotein growth factor signaling pathways.
The PTHrP/Ihh pathway
Chondrocyte proliferation and maturation in the growth
plate is regulated by a negative feedback loop of intercellu-
lar communication, mediated by the secreted signaling mol-
ecules PTHrP and Ihh [64,65]. PTHrP, a peptide hormone
with homology to parathyroid hormone, is synthesized and
secreted by periarticular perichondrial cells, and by chon-
drocytes later in development. It functions as a patterning
molecule, inhibiting chondrocyte hypertrophy near the artic-
ular ends of the developing bone, thus maintaining a pool of
proliferating cells [66]. Mutations in the PTH/PTHrP recep-
tor that result in constitutive activation cause Jansen’s chon-
drodysplasia [67]. These patients have decreased skeletal
growth, abnormal metaphases and other skeletal malforma-
tions (OMIM 156400). Ihh, a member of the hedgehog
family of cell-surface-associated ligands is expressed in the
postmitotic, prehypertrophic cells, and provides the signal
to maintain PTHrP expression at the ends of the developing
bone [65]. By inhibiting chondrocyte maturation, PTHrP
downregulates Ihh in the cells near the ends of the bone.
Ihh promotes chondrocyte proliferation and specifies
growth in the long axis through PTHrP-dependent and
PTHrP-independent mechanisms [68]. Loss of Ihh function
by gene targeting in mice results in decreased chondrocyte
proliferation, loss of PTHrP expression, and abnormal posi-
tioning of hypertrophic chondrocytes close to the articular
surface [66]. Ihh is also necessary for the signaling between
the postmitotic chondrocytes and the perichondrium to
establish and advance the bone collar [66,69]. Point muta-
tions in Ihh that may inhibit binding to its receptor causes
shortening of the digits (brachydactyly type A-1; OMIM
112500), consistent with its role in chondrocyte prolifera-
tion and bone growth [70].
The BMP pathways
BMP6 may serve a direct role in regulating chondrocyte
maturation, while other BMPs may contribute to signaling
between the chondrocytes and the perichondrium. BMP6
is expressed in prehypertrophic and hypertrophic chon-
drocytes, and several other BMPs are expressed in the
perichondrium [71–74]. Treatment of chondrogenic cul-
tures with BMP6 promotes the expression of type X colla-
gen and alkaline phosphatase [75]. Misexpression of
constitutively active BMP receptor type IA in developing
limbs, however, delays chondrocyte maturation, and like
Ihh overexpression, upregulates PTHrP [56,65]. This sug-
gests that BMP stimulation of its receptor in the diaphy-
Available online http://arthritis-research.com/content/4/2/094
Figure 1
A section through the growth plate of a fetal mouse metatarsal, 17
days post fertilization. Blue staining indicates endogenous alkaline
phosphatase activity in the hypertrophic chondrocytes, diaphyseal
perichondrium and bone collar, and primary spongiosa. Safranin O
staining of chondromucin in the cartilage matrix is red. The regions
populated by each stage of the chondrocyte lineage are shown. seal perichondrium mediates the signaling between Ihh
from the prehypertrophic chondrocytes and PTHrP
expression in the periarticular perichondrium.
The fibroblast growth factor pathways
Of the high affinity receptors for fibroblast growth factors
(FGFs), three of the five family members FGFR1, FGFR2
and FGFR3 regulate skeletal development. The importance
of FGFR3 in regulating chondrocyte proliferation and matu-
ration has been revealed by analysis of patients with acti-
vating mutations in this gene, which causes achondroplasia
(OMIM 100800), hypochondroplasia (OMIM 146000),
thanatophoric dysplasias (OMIM 187600), and other
skeletal and soft tissue disorders, depending on the muta-
tion (OMIM 134934)[63]. Su et al. [76] demonstrated that
chondrocytes from a fetus with thanatophoric dysplasia
type II exhibited increased activation of the transcription
factor STAT1, and increased expression of the cyclin-
dependent kinase inhibitor p21(Waf1/Cip1), a STAT-reg-
ulated gene. This suggests that mutations in FGFR cause
defects in EO by inhibiting chondrocyte proliferation. Sub-
sequent studies in mice and tissue culture cells have sup-
ported the hypothesis that increased FGFR activity
disrupts the normal pattern of cartilage growth and matu-
ration, at least in part by signaling through Stat molecules
and increasing cyclin-dependent kinase inhibitor expres-
sion [77–82]. Furthermore, increased FGFR signaling
causes premature apoptosis of growth plate chondrocytes
in a Stat1-dependent manner [82,83]. Conversely, the
FGFR3 null mutant mice exhibit increased chondrocyte
proliferation and increased bone growth [84]. Interest-
ingly, Ihh and PTHrP expression is decreased in mice
expressing activated mutant FGFR3 or in wild type
metatarsals grown in culture in the presence of FGF2
[85,86]. This suggests interactions between the FGF sig-
naling pathway and the PTHrP/Ihh pathways in regulating
chondrocyte proliferation and maturation, although the
precise mechanisms of these interactions is not clear.
The Cbfa1 pathway
Cbfa1 (also called Runx2,  PEBP2A  or  Osf2;
OMIM 600211) is a critical gene in the regulation of skele-
tal development as it is necessary for endochondral and
intramembranous bone formation, and it is sufficient to
induce premature and ectopic chondrocyte hypertrophy
[87–90]. Cbfa1 encodes a transcription factor containing
a conserved runt domain, that is expressed in mesenchy-
mal condensations, chondrocytes, and cells of the
osteoblast lineage [90–93]. Heterozygous loss of function
mutations in Cbfa1 cause cleidocranial dysplasia
(OMIM 119600), a syndrome that includes clavicle
hypoplasia or aplasia, failure in closure of the anterior
fontanel, and other skeletal and dental malformations [94].
In addition to the essential role that Cbfa1 plays in
osteoblast differentiation, it also regulates chondrocyte
maturation. Loss of Cbfa1 by gene targeting in mice
results in a complete lack of bone formation and a lack of
chondrocyte hypertrophy in most of the skeleton
[87,88,92,93]. Ectopic expression of Cbfa1 in nonhyper-
trophic chondrocytes of transgenic mice promotes their
hypertrophic differentiation and disrupts joint formation
[90,95]. Cbfa1 is a direct regulator of osteocalcin and
other genes in osteoblasts, and may also directly regulate
hypertrophic-chondrocyte-specific genes [89]. VEGF,
which is normally expressed in hypertrophic chondrocytes,
is not expressed in the chondrocytes of Cbfa1 null mutant
mice. Furthermore, VEGF expression is upregulated by
Cbfa1 in fibroblasts in tissue culture [96]. These data
suggest that Cbfa1 is an important regulator of EO, con-
trolling chondrocyte maturation, osteoblast differentiation,
and angiogenesis in the developing bone.
The regulation of Cbfa1 expression and activity serves as
a point of convergence of multiple signaling pathways.
Cbfa1 expression is upregulated by BMP2, BMP4 or
BMP7 treatment of multipotential, skeletal, or myogenic
cell lines [91,97–99]. The regulation of Cbfa1 by BMP
may be mediated by Msx2, since Cbfa1 expression is
decreased in Msx2 null mutant mice [39]. Negative regula-
tors of Cbfa1 expression in osteogenic cells include glu-
cocorticoid, 1,25(OH)2D3, and TGF-β [91,100,101]. The
function of Cbfa1 is repressed by its association with
Smad3 in TGF-β stimulated cells [101]. Cbfa1 expression
is upregulated in transgenic mice carrying an activated
mutant FGFR1, and upregulated in a mesenchymal cell
line treated with FGF2 or FGF8 [102]. Ihh may be both a
regulator of Cbfa1 expression and a target of Cbfa1 tran-
scriptional activity. Cbfa1 expression and bone collar for-
mation is dependent on Ihh expression in prehypertrophic
chondrocytes [66,69]. Expression of Cbfa1 in nonhyper-
trophic chondrocytes induces Ihh expression in these cells
and eventual hypertrophy [90,95]. Further study of the
regulation of Cbfa1, its protein interactions, and the
targets of its transcriptional activity will contribute to the
detailed characterization of the molecular mechanisms
regulating EO.
Joint formation
Another fate for embryonic skeletal cartilage is the forma-
tion of joints. The cartilage template for the developing
limb skeleton forms as a continuous, branched cartilage
element from the humerus/femur to the digit rays, with only
a few skeletal elements formed from independent conden-
sations [103,104]. These cartilage structures are then
segmented through the differentiation and apoptosis of
chondrocytes to form joint cavities, through a process
called cavitation. Concurrently, adjacent chondrocytes
and perichondrial cells differentiate to form articular carti-
lage and other joint-associated tissues [105,106].
Cartilage-derived morphogenetic protein 1 (CDMP1) and
its mouse homologue, Gdf5, are members of the TGF-β
Arthritis Research    Vol 4 No 2 Shum and Nuckollssuperfamily, related to BMPs. Null mutation of Gdf5 causes
shortening of the digits and defects in joint formation in the
limbs as seen in the classical mouse mutant line brachy-
podism (bp) [105,107]. Mutations in CDMP1  cause the
human skeletal disorders Grebe type chondrodysplasia
(OMIM 200700), Hunter-Thompson type acromesomelic
dysplasia (OMIM 201250) and brachydactyly type C
(OMIM 113100), which all include shortened or missing
phalanges. Gdf5 is normally expressed in developing joints.
It is one of the earliest markers of joint formation and is
strongly expressed throughout cavitation [108–110]. Gli3,
a transcription factor that functions in the hedgehog signal-
ing pathway, is also expressed in developing joints, and its
expression pattern is expanded in bp mice [110]. Focal
application of exogenous Gdf5 protein to the cartilage digit
rays of bp mouse limb buds in culture inhibits the expanded
expression of Gli3 [110]. This suggests that CDMP1/Gdf5
provides an important signal for the sites of joint formation,
and this signal regulates the expression of genes that
control chondrocyte differentiation.
Recent studies by Hartmann and Tabin [111] demon-
strated the importance of Wnt-14 in initiating joint forma-
tion and in the spacing of joints within the cartilage
condensation. Wnt-14 is a member of the large Wnt family
of secreted glycoproteins that bind to receptors of the friz-
zled family. Wnt-14 is expressed in the early joint-forming
regions of the developing chicken limb in a pattern similar
to Gdf5. In fully developed joints, however, Wnt-14 is
expressed in the joint capsule and synovial membrane,
while Gdf5 is restricted to the joint fibroarticular cartilage.
Ectopic expression of Wnt-14 in developing digits induces
morphological and molecular changes indicative of
ectopic joint formation, including inhibition of cartilage dif-
ferentiation, and upregulation of Gli3, Gdf5, autotaxin,
chordin, Wnt-4 and CD44rel expression in relative pat-
terns similar to those seen in normal joint development
[111]. Furthermore, ectopic Wnt-14 expression represses
adjacent endogenous joint development in the same carti-
lage condensation. This suggests that joint initiation by
Wnt-14 activates a signal that regulates the positioning of
the next joint in the patterning of the digits.
Study of the Wnt/frizzled pathway will contribute to an
understanding of skeletal patterning and joint formation
and may also provide molecular characterization of cellular
changes in rheumatoid arthritis. Wnt-5a and frizzled 5 are
both overexpressed in the synovial tissues of rheumatoid
arthritis patients when compared to normal joint tissue or
tissue from osteoarthritic joints [112]. This may suggest a
change in the state of differentiation of synoviocytes that
contributes to progression of the disease.
Future directions
Skeletal morphogenesis depends greatly on the patterning
and formation of cartilage, and the subsequent remodeling
of cartilage into bones or joints. Molecules such as BMPs
regulate important steps at different times in the life cycle
of cartilage. This may suggest that BMPs instruct chon-
drocytes when to change their patterns of gene expres-
sion and behavior rather than providing specific
instructions of which genes to express. The set of genes
ready for expression may be determined by the history of
signals to which the cell has been exposed, and the col-
lection of receptors, signaling molecules and transcription
factors accumulated in response to those signals. During
chondrogenesis and endochondral ossification, chondro-
cyte proliferation is regulated by FGFs, BMPs, PTHrP, Ihh,
cell–cell and cell–matrix adhesion, and biomechanical
signals. These multiple concurrent signals converge on
the regulation of cell cycle progression and cell differentia-
tion. Further study of the interaction of cartilage-associ-
ated transcription factors such as Msx2 and Cbfa1 with
cell-cycle regulators will contribute to an understanding of
the important connection between proliferation and differ-
entiation. Tissue engineering for the treatment of skeletal
diseases and disorders will depend on effective tools for
expanding populations of chondrocytes while maintaining
or restoring their state of differentiation.
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